rilonacept 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
interleukin-1 receptors 5105 501081-76-1

Description:

MoleculeDescription

Synonyms:

  • rilonacept
  • arcalyst
an anti-arthritis agent derived from IL-1R and IL-1RAcP
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
23 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Feb. 27, 2008 FDA REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site erythema 114.69 41.91 41 845 98461 90529100
Injection site reaction 69.57 41.91 28 858 92052 90535509
Chest pain 68.49 41.91 41 845 319604 90307957
Injection site mass 62.01 41.91 18 868 22072 90605489
Injection site rash 56.08 41.91 17 869 24156 90603405
Injection site pruritus 49.86 41.91 19 867 53815 90573746
Product dose omission issue 46.27 41.91 31 855 291656 90335905
Injection site pain 44.24 41.91 25 861 173674 90453887

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site erythema 131.85 44.87 43 859 94133 110494264
Injection site rash 68.79 44.87 19 883 23400 110564997
Injection site mass 67.85 44.87 19 883 24594 110563803
Product dose omission issue 66.89 44.87 38 864 321744 110266653
Injection site pain 59.73 44.87 29 873 177893 110410504
Chest pain 58.82 44.87 37 865 376338 110212059
Injection site reaction 54.01 44.87 22 880 89048 110499349
Injection site pruritus 46.56 44.87 17 885 51241 110537156

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35845 gout suppressant

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs
anakinrabasiliximabbimekizumabbrodalumabcanakinumabdaclizumabguselkumabixekizumabmirikizumabrisankizumabsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cryopyrin associated periodic syndrome indication 430079001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-1 beta Cytokine INHIBITOR Kd 12.30 DRUG LABEL DRUG LABEL
Interleukin-1 alpha Cytokine INHIBITOR Kd 11.85 DRUG LABEL
Interleukin-1 receptor antagonist protein Cytokine INHIBITOR Kd 11.22 DRUG LABEL

External reference:

IDSource
8K80YB5GMG UNII
D06635 KEGG_DRUG
4027340 VANDF
C2343589 UMLSCUI
CHEBI:749605 CHEBI
CHEMBL1201830 ChEMBL_ID
DB06372 DRUGBANK_ID
8750 INN_ID
C531377 MESH_SUPPLEMENTAL_RECORD_UI
6790 IUPHAR_LIGAND_ID
763450 RXNORM
136721 MMSL
25332 MMSL
d07138 MMSL
012583 NDDF
430868007 SNOMEDCT_US
434463003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Arcalyst HUMAN PRESCRIPTION DRUG LABEL 1 73604-914 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 160 mg SUBCUTANEOUS BLA 32 sections